Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guanze Medical Information Industry (Holding) Co (HKSE:02427) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Guanze Medical Information Industry (Holding) Co EBITDA Margin % Related Terms
Guanze Medical Information Industry (Holding) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guanze Medical Information Industry (Holding) Co EBITDA Margin % Chart
Guanze Medical Information Industry (Holding) Co Annual Data
HKSE:02427 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Guanze Medical Information Industry (Holding) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guanze Medical Information Industry (Holding) Co EBITDA Margin % vs Medical Diagnostics & Research Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guanze Medical Information Industry (Holding) Co (HKSE:02427) has a EBITDA Margin % of -42.34% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. According to the industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #136 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 67.3%.
Is Guanze Medical Information Industry (Holding) Co's EBITDA Margin % too high?
Guanze Medical Information Industry (Holding) Co's current EBITDA Margin % is -42.34%. Based on the distribution chart, Guanze Medical Information Industry (Holding) Co ranks #136 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guanze Medical Information Industry (Holding) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guanze Medical Information Industry (Holding) Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #136 out of 202 companies for EBITDA Margin %. This places Guanze Medical Information Industry (Holding) Co in the lower half of its industry. The industry median EBITDA Margin % is 5.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guanze Medical Information Industry (Holding) Co's current EBITDA Margin % is -42.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guanze Medical Information Industry (Holding) Co stock overvalued right now?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co (HKSE:02427) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.28, compared to a current price of HK$2.80 — trading 900% above its estimated fair value. The current EBITDA Margin % is -42.34%. Guanze Medical Information Industry (Holding) Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guanze Medical Information Industry (Holding) Co (HKSE:02427), the current EBITDA Margin % is -42.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guanze Medical Information Industry (Holding) Co (HKSE:02427) Overvalued in 2026?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co stock appears to be overvalued.
The current stock price of HK$2.80 is trading 900% above its estimated GF Value™ of HK$0.28.
GuruFocus considers Guanze Medical Information Industry (Holding) Co to be Significantly Overvalued.
Key valuation signals for HKSE:02427:
EBITDA Margin %: -42.34%
GF Value™: HK$0.28 vs. price of HK$2.80 (900% above fair value)
No single metric tells the full story. See the HKSE:02427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guanze Medical Information Industry (Holding) Co Business Description
Guanze Medical Information Industry (Holding) Co Ltd is a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. The company generates the majority of its revenue from the PRC.
52GF Score
Get the complete analysis for HKSE:02427
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02427 has been successfully added to your 
